Study of the Effects of dasatinib and quercetin on IPF

What we are studying

Medical scientists have found that most cells in your body turn over rapidly, but with age some cells become inflamed. This means the cells no longer turn over and can become destructive to nearby cells, creating more inflamed cells and releasing signals that can increase inflammation in the rest of the body. Patients with IPF have even greater numbers of inflamed cells than other older people, but researchers are not sure how this affects their disease. Investigationers have found ways to eliminate the cells in the body that have become inflamed and destructive; the most effective way to target these cells in animals is to use a combination therapy of dasatinib and quercetin. Dasatinib is a chemotherapy drug currently used to treat leukemia. Dasatinib has been approved by the US Food and Drug Administration (FDA), but it has not been approved for use in IPF or for use to reduce the number of inflamed cells. Quercetin is a flavonoid found in black currants, cilantro, red onion, watercress, cranberries and other fruits and herbs, and is generally recognized as safe by the Food and Drug Administration (FDA). In animal models of IPF and aging, dasatinib and quercetin can reduce the number of inflamed cells and improve endurance, but the combination treatment has never been studied in people. The purpose of this research study is to test the safety of dasatinib and quercetin and see what effects (good and bad) it has on you, the number of inflamed cells you have and your IPF.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 50+

Eligibility Criteria

  • Participants must have a clinical diagnosis of idiopathic pulmonary fibrosis (IPF) OR biopsy showing usual interstitial pneumonia (UIP)
  • On stable therapy with nintedanib (Ofev) or pirfenidone (Esbriet) over the past 3 months OR not taking nintedanib (Ofev) or pirfenidone (Esbriet) if you have previously not tolerated one of those medications or if those medications have not yet been prescribed or used

What is involved

  • 4 total visits over 1 month that consists of: 3 blood draws
  • Physical function testing
  • Lung function testing
  • 2 skin biopsies
  • And 3 weeks of study drug

Compensation

You will be paid $150 if you complete all the scheduled study visits. If you withdraw for any reason from the study before completion you will be paid $75 for each complete study visit (baseline and follow-up).

Contact Information

Study Coordinator
Lindsay Gordon
Email
[email protected]
Phone
-8540
Principal Investigator
Stephen Kritchevsky, PhD

подробнее

ссылка

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.